|
Forecast Period
|
2025-2029
|
|
Market Size (2023)
|
USD 13.58 Billion
|
|
CAGR (2024-2029)
|
9.17%
|
|
Fastest Growing Segment
|
Metered Dose Inhaler (MDI)
|
|
Largest Market
|
North America
|
Market Overview
Global Digital Dose Inhaler Market was valued at USD 13.58
Billion in 2023 and is anticipated to project impressive growth in the forecast
period with a CAGR of 9.17% through 2029. The Digital Dose Inhaler market
refers to the sector encompassing the development, manufacturing, and
distribution of inhalers equipped with digital technology. These advanced
devices not only deliver medication to patients with respiratory conditions
such as asthma or COPD (Chronic Obstructive Pulmonary Disease) but also track
usage data. This valuable information can be shared with healthcare providers
to optimize treatment plans and improve patient outcomes.
Market Overview
Increase in Prevalence of Chronic Respiratory
Diseases
Chronic respiratory diseases (CRDs) are complex
multifactorial disorders encompassing the air passages and other pulmonary
structures. Asthma, chronic obstructive pulmonary disorder (COPD), cystic
fibrosis, lung cancer and sleep apnea are some of the leading chronic
respiratory diseases which have emerged with a lucrative rate over recent
years. In 2019, CRDs were the third leading cause accountable for 4.0 million
deaths with a prevalence of 454.6 million instances across the world. According
to the reports published by Pan American Health Organization (PAHO), it has
been observed that particularly in American region, CRDs were responsible for
approximately 534,242 fatalities in 2019 encompassing 267,516 deaths among
males and 266,725 deaths among females. Among various diseases, asthma has
prevailed as the significant ailment which have increased the worldwide demand
of digital dose inhalers. China, India, United States of America, Indonesia,
Brazil, and Ethiopia are some of the major countries which have recorded
highest number of asthma cases in their nation. As per the statistics
published by Allergy and Asthma Networks, it has been observed that more than
26 million people are suffering from asthma in United States. Moreover, asthma
affects around 8% of adults and 6.5% of children every year in the country. Over
20 clinical trials of digital inhalers in asthma or COPD collectively show
enhancement in medication compliance, exacerbation susceptibility, and patient
results with digital inhalers. The most common commercially available digital
inhaler devices for monitoring inhaler use are Propeller Health, Teva Digihaler,
Amiko Respiro, and Adherium Hailie. The digital dose inhaler is a device that
delivers a precise quantity of medication to the respiratory system, in the
form of a brief burst of atomized medicine that is self-administered by the
patient through breathing in. The digital inhaler is equipped with integrated
sensors that identify the usage of the inhaler and assess the rate of
inhalation, according to the release and dosage control. Therefore, capability
of digital dose inhalers to control the effects of chronic respiratory diseases
is anticipated to register an impressive growth to Global Digital Dose Inhaler
Market in the forecast period.
Introduction of New Products
Growth in launches of new products in the market
associated with digital dose inhalers are further expected to propel the growth
of market in upcoming years. In February 2022, Honeywell International Inc., an
American global corporation, and AstraZeneca plc, a global pharmaceutical
company, declared their collaboration to create inhalers for respiratory
conditions by utilizing HFO-1234ze propellant. This propellant significantly
reduces the Global Warming Potential (GWP) by 99.9% compared to the propellants
currently employed in respiratory medications. Enerzair Breezhaler developed by
Novartis AG, a Swiss pharmaceutical corporation, has been granted its
authorization from the European Commission (EC), making it the first digital
asthma treatment in the EU to be recommended coupled with a sensor and
application. Moreover, in September 2022, Teva Pharmaceutical Industries Ltd.
has introduced two digital inhalers in the United States namely ArmonAir
Digihaler (fluticasone propionate) and AirDuo Digihaler (fluticasone propionate
and salmeterol). To address the errors in device operations, a fully digital breath-activated
inhaled (DBAI) delivery system has been created with incorporated firmware and
software. The DBAI is an innovative measured dosage inhaler created to surpass
limitations of currently accessible pulmonary medication delivery apparatus. The
main design elements of the Pneuma Inhaler comprise of a vibrating plate
piezoelectric spray expeller, a contrasting pressure sensor, and a
microprocessor that regulates dosage administration, user alerts, and dosage
counting.
Surge in Technological Advancements
Increase in technological advancements related to
digital dose inhalers is also one of the remarkable factors which is attributed
to register a lucrative growth to Global Digital Dose Inhaler market in the
forecast period. Aptar Pharma, a specialist in drug delivery, services, and
innovative material science solutions has introduced HeroTracker Sense, a
digital solution for monitoring respiratory health. This revolutionary
technology transforms a regular metered dose inhaler (pMDI) into a smart
connected healthcare device. HeroTracker Sense is specifically developed to
enhance the well-being of individuals across the world who are affected with
chronic respiratory ailments like asthma, COPD, Cystic Fibrosis, and other
respiratory disorders caused by COVID-19. Its primary purpose is to monitor the
usage of metered-dose inhalers (MDIs) and promote better compliance with
prescribed treatment. The in-built sensors in the device allow for the
generation and supply of data regarding the synchronization of inhalation with
device activation, the speed of airflow, and the duration of each inhalation.
Moreover, a recent global study conducted by RCSI University of Medicine and
Health Sciences on 6th April 2023 has revealed substantial possibilities for
digital technology to improve asthma management for patients. Developed in
collaboration between RCSI and Trinity College Dublin, the INCA tool offers an
evaluation of how patients utilize their inhalers, by measuring sound-wave
signals emitted by the inhaler. The information is then transmitted to the
patient's healthcare provider through a digital clinical decision platform that
offers recommendations for the most effective treatment. Additionally, INCA
devices can assist in distinguishing between individuals with severe asthma and
those with difficult-to-manage asthma.
Growth in Geriatric Population
Rise in geriatric population and their increased
vulnerability towards certain respiratory disorders are also supporting the
market growth in the forecast period. According to the data released by
Population Reference Bureau, it has been observed that China has the highest
percentage of elderly people, with approximately 166.37 million individuals
aged 65 and above out of the total population. India comes next with 84.9
million individuals, followed by the United States with 52.76 million
individuals, Japan with 35.58 million individuals, and the Russian Federation
with 21.42 million individuals aged 65 and above out of the entire population. Asthma
is prevalent in individuals aged above 65 years and significantly reduces both
mental and physical well-being. Use of hydrofluoroalkane (HFA) compressed
metered dose inhaler (MDI) with a valved holding chamber, a breath-actuated dry
powder inhaler, or a nebulizer can enhance the administration of medication in
cases where the technique is suboptimal. Therefore, enhanced properties of
digital dose inhalers to address such medical issues in elder population is
expected to drive the market growth in the futuristic period.
Download Free Sample Report
Key Market Challenges
High Production Costs
High production costs pose a significant barrier to
the widespread adoption of digital dose inhalers globally. The incorporation of
sophisticated technologies such as sensors, connectivity features, and mobile
applications into these devices results in substantial manufacturing expenses.
These costs encompass not only the development and integration of the
technology itself but also quality control measures to ensure reliability and
accuracy. Additionally, the need for compliance with regulatory standards further
adds to the production costs. As a consequence, digital dose inhalers are often
priced at a premium compared to traditional inhalers, making them less
accessible to patients and healthcare systems with limited financial resources.
Furthermore, reimbursement challenges may deter healthcare providers from
prescribing digital inhalers, particularly in regions where reimbursement rates
do not adequately cover the higher cost of these devices. Consequently, despite
the potential benefits offered by digital dose inhalers in improving medication
adherence and patient outcomes, the high production costs associated with these
devices serve as a deterrent to their widespread adoption globally.
Maintenance and Upkeep
Maintenance and upkeep requirements present a significant
challenge to the widespread adoption of digital dose inhalers globally. While
these advanced devices offer innovative features such as dose tracking and
real-time data monitoring, they also require regular maintenance and updates to
ensure optimal functionality. Patients using digital inhalers may encounter
difficulties with software glitches, connectivity issues, or battery life,
necessitating troubleshooting and technical support. Moreover, healthcare
providers must invest time and resources in training patients on how to use and
maintain these devices properly. The need for ongoing maintenance and support
increases the overall cost of ownership for digital dose inhalers, potentially
deterring both patients and healthcare providers from embracing these
technologies, particularly in resource-limited settings. Additionally, concerns
about device reliability and the potential for disruptions in medication
delivery may further dampen demand. Therefore, despite the promise of improved
medication adherence and patient engagement, the maintenance and upkeep
requirements associated with digital dose inhalers serve as barriers to their
widespread adoption globally.
Key Market Trends
Innovation in Drug Delivery Systems
Innovation in drug delivery systems, particularly
in the realm of digital dose inhalers, is driving a notable increase in demand
globally. Digital dose inhalers represent a significant advancement in
respiratory medication delivery, offering precise dosing, enhanced patient
adherence, and real-time tracking of usage data. These inhalers integrate smart
technology such as sensors, connectivity features, and mobile applications,
enabling patients to monitor their medication intake and receive timely
reminders for doses. Moreover, healthcare providers can remotely access and
analyze inhaler usage data to tailor treatment plans and provide personalized
care. The advent of digital dose inhalers is particularly beneficial for
managing chronic respiratory conditions such as asthma and chronic obstructive
pulmonary disease (COPD), where adherence to medication regimens is critical
for disease management. Additionally, the convenience, accuracy, and improved
patient engagement offered by digital dose inhalers are driving their adoption
among healthcare professionals and patients alike, thereby fueling the global
demand for these innovative drug delivery devices.
Investment in Health Tech Startups
Investment in health tech startups is significantly
contributing to the growing demand for digital dose inhalers on a global scale.
As venture capital continues to pour into the healthcare sector, there is a
particular emphasis on supporting innovative solutions that improve patient
outcomes and enhance healthcare delivery. Digital dose inhalers represent a
prime example of such innovation, offering advanced features like dose
tracking, medication reminders, and real-time data monitoring. With startups
focusing on developing and refining these technologies, there's a surge in
awareness and adoption of digital inhalers among healthcare providers and
patients alike. Additionally, strategic partnerships between health tech
startups, pharmaceutical companies, and healthcare providers are driving the
integration of digital inhalers into clinical practice. These collaborations
facilitate the development of tailored solutions and expand market access for
digital dose inhalers globally. As investment in health tech startups continues
to grow, fueled by the promise of transformative healthcare solutions, the
demand for digital dose inhalers is poised to rise, revolutionizing respiratory
care on a global scale.
Segmental Insights
Product Insights
Based on the product, the
Global Digital Dose Inhaler Market has witnessed a significant rise in the
popularity of the Metered Dose Inhaler (MDI) segment. MDIs have become widely
favored among patients due to their exceptional convenience, portability, and
ease of use. These attributes have made MDIs the dominant choice for
individuals requiring regular medication doses to manage conditions such as
asthma and COPD (Chronic Obstructive Pulmonary Disease).
Furthermore, the market has
seen remarkable advancements in digital integration, which have further
solidified the position of MDIs. The incorporation of features like dose
counters and connectivity with health tracking apps has enhanced the overall
effectiveness and user experience of MDIs. These digital enhancements provide patients
with greater control and awareness of their medication usage, enabling them to
better manage their respiratory conditions. As a result, the MDI segment has
experienced continuous growth and shows immense potential for the future. With
ongoing advancements in technology and increasing demand for improved
respiratory care, the Global Digital Dose Inhaler Market is poised to witness
further expansion and innovation in the coming years.
Type Insights
Based on the Type segment, within
the Global Digital Dose Inhaler Market, generic medications are gaining a
significant foothold due to their cost-effectiveness and the growing support
from regulations favouring generic drug prescription. These medications, which
are typically more affordable than their branded counterparts, offer a viable
option for patients and healthcare systems seeking to manage costs without
compromising on quality. While branded medications continue to dominate in
terms of initial market entry and innovation, the price sensitivity of healthcare
systems and patients alike is shifting the balance toward generics.
Furthermore, the recent
patent expirations of leading branded inhalers have paved the way for generic
alternatives to capture an increasing market share. This presents an opportunity
for generic manufacturers to enter the market with their own innovative
solutions, providing patients with a wider range of choices. As the demand for
affordable yet effective inhaler options continue to rise, the market landscape
is expected to evolve further, with generic medications playing a critical role
in meeting the needs of patients and healthcare systems worldwide.
Download Free Sample Report
Regional Insights
The North American region, particularly the United
States, is currently dominating the Global Digital Dose Inhaler Market. This
dominance can be attributed to several factors that contribute to the region's
success. There is a high level of health awareness among the population, which
drives the demand for advanced healthcare solutions. Secondly, the region
boasts a well-developed healthcare infrastructure that supports the widespread
adoption of digital health technologies, including digital inhaler devices.
Furthermore, the pharmaceutical and biotechnology sectors in North America have
made significant investments in research and development, resulting in the
continuous innovation of digital inhaler technologies. This investment not only
fuels the growth of the market but also ensures that patients have access to
cutting-edge devices that improve their quality of life.
Moreover, the presence of key market players in the
region plays a crucial role in supporting rapid innovation and accessibility to
digital inhaler devices. These industry leaders collaborate with healthcare
providers, researchers, and patients to develop and distribute innovative
solutions that address the specific needs of the market. The North American
region, particularly the United States, is at the forefront of the Global
Digital Dose Inhaler Market due to high health awareness, advanced healthcare
infrastructure, widespread adoption of digital health technologies, significant
investment in research and development, and the presence of key market players.
Key Market Players
- 3M Company
- AstraZeneca Plc.
- Glenmark Pharmaceuticals Ltd.
- Novartis AG
- Propeller Health Inc.
- Opko Health, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Beximco Pharmaceuticals Limited
- GlaxoSmithKline Plc.
- Mundipharma Deutschland GmbH & Co. KG
|
By Product
|
By Type
|
By Indication
|
By Region
|
|
- Metered Dose Inhaler (MDI)
- Dry Powder Inhaler (DPI)
|
- Branded Medication
- Generic Medication
|
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
|
|
|
|
|
Report Scope:
In this report, the Global Digital Dose Inhaler Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Digital Dose Inhaler Market, By Product:
o Metered Dose Inhaler (MDI)
o Dry Powder Inhaler (DPI)
- Digital Dose Inhaler Market, By Type:
o Branded Medication
o Generic Medication
- Digital Dose Inhaler Market, By Indication:
o Asthma
o Chronic Obstructive
Pulmonary Disease (COPD)
o Others
- Digital Dose Inhaler Market,
By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Digital Dose Inhaler Market.
Available Customizations:
Global Digital Dose Inhaler market report with
the given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Digital Dose Inhaler Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]